Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDUFA II: ANDAs, Not Facilities Will Govern Revenue

Executive Summary

Since applications comprise most of the workload, they will be the focus in the next generic drug user fee cycle.

You may also be interested in...



Pre-ANDA Meetings Proving Tough To Get – Nearly Half Of Requests Denied

During first half of fiscal 2018, US FDA only granted 16 of 31 pre-ANDA meeting requests, but said it was to ensure meetings were productive.

Pre-ANDA Meetings Proving Tough To Get – Nearly Half Of Requests Denied

During first half of fiscal 2018, US FDA only granted 16 of 31 pre-ANDA meeting requests, but said it was to ensure meetings were productive.

Generic User Fee Transition A Little Bumpy For Contract Manufacturers

Problems with self-identification process caused by timing of legislative renewal may have affected figures used by US FDA to calculate FY 2018 GDUFA fees.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132082

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel